vs
CytomX Therapeutics, Inc.（CTMX）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是CytomX Therapeutics, Inc.的1.0倍（$19.6M vs $18.7M），CytomX Therapeutics, Inc.净利率更高（-0.8% vs -177.4%，领先176.6%），STANDARD BIOTOOLS INC.同比增速更快（-11.5% vs -25.7%），CytomX Therapeutics, Inc.自由现金流更多（$-15.8M vs $-23.1M），过去两年STANDARD BIOTOOLS INC.的营收复合增速更高（-12.2% vs -15.9%）
CytomX Therapeutics是一家临床阶段生物技术公司，专注于创新癌症免疫疗法研发，依托专有的Probody技术平台开发仅在肿瘤微环境中激活的靶向疗法，可降低脱靶毒性，管线覆盖多种实体瘤适应症，还与全球头部药企合作推进相关治疗方案开发。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
CTMX vs LAB — 直观对比
损益表 — Q2 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.7M | $19.6M |
| 净利润 | $-154.0K | $-34.7M |
| 毛利率 | — | 48.5% |
| 营业利润率 | -6.9% | -168.5% |
| 净利率 | -0.8% | -177.4% |
| 营收同比 | -25.7% | -11.5% |
| 净利润同比 | 97.6% | -28.8% |
| 每股收益（稀释后） | — | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q3 25 | — | $19.6M | ||
| Q2 25 | $18.7M | $21.8M | ||
| Q1 25 | $50.9M | $40.8M | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $33.4M | $22.1M | ||
| Q2 24 | $25.1M | $22.5M | ||
| Q1 24 | $41.5M | $45.5M | ||
| Q4 23 | $26.6M | $28.2M |
| Q3 25 | — | $-34.7M | ||
| Q2 25 | $-154.0K | $-33.5M | ||
| Q1 25 | $23.5M | $-26.0M | ||
| Q4 24 | $18.9M | — | ||
| Q3 24 | $5.7M | $-26.9M | ||
| Q2 24 | $-6.5M | $-45.7M | ||
| Q1 24 | $13.8M | $-32.2M | ||
| Q4 23 | $837.0K | $-19.8M |
| Q3 25 | — | 48.5% | ||
| Q2 25 | — | 48.8% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 54.9% | ||
| Q2 24 | — | 46.1% | ||
| Q1 24 | — | 53.1% | ||
| Q4 23 | — | 47.6% |
| Q3 25 | — | -168.5% | ||
| Q2 25 | -6.9% | -118.1% | ||
| Q1 25 | 44.4% | -80.8% | ||
| Q4 24 | 46.4% | — | ||
| Q3 24 | 12.3% | -120.9% | ||
| Q2 24 | -33.7% | -134.5% | ||
| Q1 24 | 28.1% | -132.2% | ||
| Q4 23 | -2.3% | -75.9% |
| Q3 25 | — | -177.4% | ||
| Q2 25 | -0.8% | -153.7% | ||
| Q1 25 | 46.2% | -63.8% | ||
| Q4 24 | 49.6% | — | ||
| Q3 24 | 17.2% | -122.0% | ||
| Q2 24 | -26.0% | -203.3% | ||
| Q1 24 | 33.3% | -70.6% | ||
| Q4 23 | 3.1% | -70.2% |
| Q3 25 | — | $-0.09 | ||
| Q2 25 | — | $-0.09 | ||
| Q1 25 | — | $-0.07 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.07 | ||
| Q2 24 | — | $-0.12 | ||
| Q1 24 | — | $-0.27 | ||
| Q4 23 | — | $-0.24 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $49.0M | $129.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $119.9M | $399.7M |
| 总资产 | $175.1M | $539.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q3 25 | — | $129.4M | ||
| Q2 25 | $49.0M | $158.6M | ||
| Q1 25 | $47.6M | $150.9M | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $40.6M | $210.6M | ||
| Q2 24 | $43.2M | $269.8M | ||
| Q1 24 | $36.2M | $287.1M | ||
| Q4 23 | $17.2M | $51.7M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | — | $55.0M | ||
| Q4 23 | — | $63.5M |
| Q3 25 | — | $399.7M | ||
| Q2 25 | $119.9M | $424.5M | ||
| Q1 25 | $25.0M | $454.6M | ||
| Q4 24 | $-456.0K | — | ||
| Q3 24 | $-23.5M | $489.3M | ||
| Q2 24 | $-31.2M | $510.3M | ||
| Q1 24 | $-31.7M | $577.3M | ||
| Q4 23 | $-47.4M | $-148.1M |
| Q3 25 | — | $539.6M | ||
| Q2 25 | $175.1M | $557.0M | ||
| Q1 25 | $98.5M | $579.6M | ||
| Q4 24 | $120.5M | — | ||
| Q3 24 | $139.0M | $681.5M | ||
| Q2 24 | $159.2M | $708.7M | ||
| Q1 24 | $184.7M | $777.7M | ||
| Q4 23 | $201.8M | $323.1M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.10× | ||
| Q4 23 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-15.8M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | $-15.8M | $-23.1M |
| 自由现金流率自由现金流/营收 | -84.6% | -118.1% |
| 资本支出强度资本支出/营收 | 0.1% | 4.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-77.7M | $-111.1M |
8季度趋势，按日历期对齐
| Q3 25 | — | $-22.2M | ||
| Q2 25 | $-15.8M | $-20.7M | ||
| Q1 25 | $-21.0M | $-30.3M | ||
| Q4 24 | $-19.9M | — | ||
| Q3 24 | $-20.7M | $-27.9M | ||
| Q2 24 | $-19.5M | $-39.0M | ||
| Q1 24 | $-26.0M | $-62.5M | ||
| Q4 23 | $-22.0M | $-14.1M |
| Q3 25 | — | $-23.1M | ||
| Q2 25 | $-15.8M | $-22.6M | ||
| Q1 25 | $-21.2M | $-35.3M | ||
| Q4 24 | $-20.0M | — | ||
| Q3 24 | $-20.7M | $-30.1M | ||
| Q2 24 | $-19.6M | $-41.0M | ||
| Q1 24 | $-26.2M | $-63.3M | ||
| Q4 23 | $-22.2M | $-14.1M |
| Q3 25 | — | -118.1% | ||
| Q2 25 | -84.6% | -103.6% | ||
| Q1 25 | -41.6% | -86.6% | ||
| Q4 24 | -52.5% | — | ||
| Q3 24 | -62.1% | -136.4% | ||
| Q2 24 | -78.2% | -182.2% | ||
| Q1 24 | -63.1% | -138.9% | ||
| Q4 23 | -83.5% | -50.2% |
| Q3 25 | — | 4.5% | ||
| Q2 25 | 0.1% | 8.7% | ||
| Q1 25 | 0.2% | 12.4% | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.1% | 10.2% | ||
| Q2 24 | 0.4% | 8.6% | ||
| Q1 24 | 0.3% | 1.7% | ||
| Q4 23 | 1.0% | 0.3% |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — | ||
| Q4 23 | -26.24× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
